go-v.orgdoi

Role of indacaterol in the management of asthma and chronic obstructive pulmonary disease

Federico Lorenzo Dente, Elena Bacci, Barbara Vagaggini, Pierluigi Paggiaro · Clinical Investigation · 2011

  • DOI 10.4155/cli.11.18
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2011

Abstract

Indacaterol is the first of a new category of inhaled β2-agonists with a very long duration of action that allows for once-daily administration. The bronchodilation induced by indacaterol is more persistent than that caused by the current long-acting β2-agonists (LABAs; salmeterol and formoterol), and therefore, for this new compound, the word ‘ultra-LABA’ has been created. Indacaterol is an agonist with high intrinsic efficacy and a rapid onset (bronchodilation may reach a maximum after 5–30 min) similar to salbutamol and formoterol, but with a longer duration of action.

The long-lasting bronchodilation up to 24 h has been largely demonstrated in several single-dose or short-term treatment studies with different doses of indacaterol. The increase in the forced expiratory volume in 1 s measured 24 h after indacaterol administration may reach up to 300 ml in asthma and 200 ml in chronic obstructive pulmonary disease (COPD). This long-lasting stabilization of the airway caliber may potentially translate int...

Open the resolved locator · 10.4155/cli.11.18

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 04:44 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.11.18
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.